Thyroid and TRH Analogues
5 compounds in this family, each with its recorded mechanism, routes of administration, safety notes and references to published literature.
- MontirelinMontirelin (also known as NS‑3 or montirelin hydrate) is a synthetic analogue of thyrotropin‑releasing hormone (TRH) approved for prescription use in Japan. It is marketed for the treatment of disturbance of consciousness following head trauma and is administered orally. As a member of the TRH analogue family, it is intended to act on central nervous system pathways to aid recovery of alertness.
- OrotirelinOrotirelin (CG‑3703) is a synthetic analogue of thyrotropin‑releasing hormone (TRH) engineered for resistance to enzymatic breakdown. It is an approved prescription peptide that can be given intravenously or orally. Pre‑clinical studies show it modulates central neurotransmitter systems, influences prolactin release, and improves wakefulness and survival in animal models of narcolepsy and traumatic brain injury.
- PosatirelinPosatirelin is an investigational synthetic tripeptide that mimics thyrotropin‑releasing hormone (TRH). Developed as a neuroactive agent, it has been evaluated primarily for cognitive impairment in vascular dementia and Alzheimer’s disease, and for functional recovery after focal cerebral ischemia in animal models.
- ProtirelinProtirelin, also known as thyrotropin‑releasing hormone (TRH) analogue, is a synthetic peptide approved for prescription use, administered intravenously. It has been investigated as a neuro‑modulatory agent to aid recovery of consciousness after head trauma, improve cognitive function after stroke, reduce psychotic symptoms in schizophrenia, and as an adjunct in amyotrophic lateral sclerosis (ALS). Experimental work also explores its anticonvulsant potential.
- TaltirelinTaltirelin is a synthetic, orally active analogue of thyrotropin‑releasing hormone (TRH). It is approved in Japan (trade name Ceredist) for the treatment of spinocerebellar degeneration and has been investigated in other cerebellar ataxias, experimental models of brain injury, and as a potential adjuvant to immune‑checkpoint blockade.